Ultrasound-guided intratumoral delivery of doxorubicin from in situ forming implants in a hepatocellular carcinoma model

Luis Solorio, Hanping Wu, Christopher Hernandez, Mihika Gangolli, Agata A. Exner

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Background: Hepatocellular carcinomas are frequently nonresponsive to systemically delivered drugs. Local delivery provides an alternative to systemic administration, maximizing the dose delivered to the tumor, achieving sustained elevated concentrations of the drug, while minimizing systemic exposure. Results: Ultrasound-guided deposition of doxorubicin (Dox)-eluting in situ forming implants (ISFI) in an orthotopic tumor model significantly lowers systemic drug levels. As much as 60 μg Dox/g tumors were observed 21 days after ISFI injection. Tumors treated with Dox implants also showed a considerable reduction in progression at 21 days. Conclusion: Dox-eluting ISFIs provide a promising platform for the treatment of hepatocellular carcinomas by which drug can be delivered directly into the lesion, bypassing distribution and elimination by the circulatory system.

Original languageEnglish (US)
Pages (from-to)201-212
Number of pages12
JournalTherapeutic Delivery
Volume7
Issue number4
DOIs
StatePublished - Apr 2016
Externally publishedYes

Keywords

  • drug delivery
  • hepatocellular carcinoma
  • in situ forming implant
  • phase inversion
  • ultrasound

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Ultrasound-guided intratumoral delivery of doxorubicin from in situ forming implants in a hepatocellular carcinoma model'. Together they form a unique fingerprint.

Cite this